Share Buyback

Amid market volatility and a green energy push, Devon's CEO will outline the firm's strategy for navigating a complex 2026 at a top industry event.

The Danish firm scraps its 2025 revenue forecast, accepting a larger loss in a bold move to secure more lucrative future deals for its key drug candidates.

Mount Logan Capital offers shareholders a 14% premium in a $15M tender offer, signaling confidence despite mixed financials and a complex market identity.

Eightco Holdings bets big on its own stock with a $125M buyback, banking on its Worldcoin treasury and a vision for AI-proof digital identity.

With $13.2 billion in assets and 3.41% of all ETH, Bitmine is on a quest for market dominance. A crucial shareholder vote will decide its future.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

After a turbulent year, the sleep apnea device maker aims to prove its rocky product launch is behind it and convince investors of a strong 2026.

EUDA Health's new Helixé 2.0 supplement boasts enhanced potency, nano-delivery tech, and Halal certification to capture the booming global wellness market.

Tevogen's Dr. Ryan Saadi donates over $88,000 in company stock to a UN-recognized charity, bolstering educational programs for underserved children.

American Express has locked in its 2026 earnings call schedule. Here’s what investors and analysts will be watching for amid shifting economic signals.

A monumental shift in U.S. drug policy as cannabis is rescheduled. See what this means for Verano, Wall Street, and the future of the industry.

Ninepoint Partners doubles its energy fund's target yield to a massive 14%. We dig into the sustainability, risks, and the new reality of energy profits.

Amid a lagging stock price, Western Uranium & Vanadium is launching a significant share buyback, signaling deep confidence in its undervalued assets.

IGM Financial has nearly doubled its share buyback authorization, a bold move signaling deep confidence. What does this mean for investors and the industry?

As Simply Good Foods preps its Q1 report, investors weigh Quest's strong growth against the ongoing struggles of its Atkins brand and market pressures.

Amid rising food insecurity, US Foods delivered nearly $12.5M in aid, powered by a 70% surge in employee volunteerism and new strategic programs.

A breakthrough clinical trial and a savvy financial move could net Fractyl Health $18M to advance its novel obesity treatment beyond the GLP-1 boom.

Kodiak Sciences is raising crucial capital with a stock offering, diluting investors but fueling its late-stage retinal drugs. Is this a necessary lifeline or a red flag?

indie Semiconductor is aggressively using stock grants to lure top engineers for its ADAS future. But what is the cost of this talent war for investors?

This REIT's stock is worth millions, but it claims its apartments are worth much more. Can a bold strategic review unlock this hidden value for investors?